RivoceranibHaemafecia following off-label treatment: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2018年 / 1721卷 / 1期

关键词：

D O I：

10.1007/s40278-018-52300-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：263 / 263

相关论文

共 50 条

[41] DaratumumabHypogammaglobulinemia following off-label use: case report
[J]. Reactions Weekly, 2019, 1744 (1) : 111 - 111
[42] TocilizumabNeutropenia following off-label use: case report
[J]. Reactions Weekly, 2021, 1853 (1) : 446 - 446
[43] NivolumabPsoriasis following an off-label use: case report
[J]. Reactions Weekly, 2018, 1717 (1) : 214 - 214
[44] SunitinibCardiomyopathy following off-label use: case report
[J]. Reactions Weekly, 2023, 1971 (1) : 240 - 240
[45] GlibenclamideHypoglycaemia following off-label use: case report
[J]. Reactions Weekly, 2021, 1857 (1) : 162 - 162
[46] PrednisoloneInefficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1910 (1) : 405 - 405
[47] ClonazepamMisidentification following off-label use: case report
[J]. Reactions Weekly, 2022, 1926 (1) : 171 - 171
[48] RituximabAgranulocytosis following off-label use: case report
[J]. Reactions Weekly, 2018, 1712 (1) : 482 - 482
[49] SirolimusPneumonia following off-label use: case report
[J]. Reactions Weekly, 2020, 1800 (1) : 269 - 269
[50] TolvaptanHypernatraemia following off-label use: case report
[J]. Reactions Weekly, 2019, 1753 (1) : 326 - 326

← 1 2 3 4 5 →